title: Survivin inhibition via EZN-3042 in canine lymphoma and osteosarcoma.
abstract: Canine lymphoma (LSA) and osteosarcoma (OS) have high mortality rates and remain in need of more effective therapeutic approaches. Survivin, an inhibitor of apoptosis (IAP) family member protein that inhibits apoptosis and drives cell proliferation, is commonly elevated in human and canine cancer. Survivin expression is a negative prognostic factor in dogs with LSA and OS, and canine LSA and OS cell lines express high levels of survivin. In this study, we demonstrate that survivin downregulation in canine LSA and OS cells using a clinically applicable locked nucleic acid antisense oligonucleotide (EZN-3042, Enzon Pharmaceuticals, Piscataway Township, NJ, USA) inhibits growth, induces apoptosis and enhances chemosensitivity in vitro, and inhibits survivin transcription and protein production in orthotopic canine OS xenografts. Our findings strongly suggest that survivin-directed therapies might be effective in treatment of canine LSA and OS and support evaluation of EZN-3042 in dogs with cancer.
authors.affiliation: Flint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.|Cell and Molecular Biology Graduate Program, Colorado State University, Fort Collins, CO, USA.
authors.forename: J K
authors.initials: JK
authors.lastname: Shoeneman
authors.affiliation: Flint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.|Cell and Molecular Biology Graduate Program, Colorado State University, Fort Collins, CO, USA.|Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
authors.forename: E J
authors.initials: EJ
authors.lastname: Ehrhart
authors.affiliation: Flint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.|Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, USA.
authors.forename: J B
authors.initials: JB
authors.lastname: Charles
authors.affiliation: Flint Animal Cancer Center, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.|Cell and Molecular Biology Graduate Program, Colorado State University, Fort Collins, CO, USA.
authors.forename: D H
authors.initials: DH
authors.lastname: Thamm
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D004283:Dog Diseases / Q000188:drug therapy / Q000378:metabolism*; D004285:Dogs; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D051034:Inhibitor of Apoptosis Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008223:Lymphoma / Q000188:drug therapy / Q000662:veterinary*; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009841:Oligonucleotides / Q000494:pharmacology*; D012516:Osteosarcoma / Q000188:drug therapy / Q000662:veterinary*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism
chemical_list: C552302:EZN 3042; D051034:Inhibitor of Apoptosis Proteins; D009841:Oligonucleotides; D012333:RNA, Messenger
keywords: EZN-3042; canine cancer; comparative oncology; lymphoma; osteosarcoma; survivin